Bio-Path Holdings, Inc. · OTC:BPTH

Bio-Path — Investor Presentation (October 2017)

20 slides from Bio-Path's investor presentation, October 2017

  1. Slide 1: Company Overview October 2017

    Slide 1: Company Overview October 2017

    Company Overview October 2017 “A new path in DNA-powered medicine” 1

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This Presentation contains forward-looking statements with respect to business conducted by Bio-Path Holdings, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will

  3. Slide 3: IP and Financial Snapshot

    Slide 3: IP and Financial Snapshot

    IP and Financial Snapshot Intellectual Property • Original patents licensed from MD Anderson • New composition and methods of use patents filed to cover DNAbilize® technology, solely owned by Bio-Path extends protection for 20 years • Notice of allowance July 2017 Financial Snapshot • Ticker: NASDAQ

  4. Slide 4: DNAbilize Technology Platform

    Slide 4: DNAbilize Technology Platform

    DNAbilize® Technology Platform ✓ Enables the development and delivery of systemic intravenous DNA treatments for a broad spectrum of cancers as well as diseases outside of cancer ✓ DNAbilize® is a Platform Technology with the potential to treat a number of oncology targets and other diseases ➢ Only

  5. Slide 5: Investment Highlights

    Slide 5: Investment Highlights

    Investment Highlights • Next generation DNA based therapeutics Broad Vision, Focused • Original technology licensed from The MD Anderson Cancer Center with Strategy significant improvements from Bio-Path • Lead candidate, prexigebersen, in Phase II for acute myeloid leukemia and Clinical Stage Pipel

  6. Slide 6: DNAbilize Technology Profile: A Targeted Method for Treating Disease

    Slide 6: DNAbilize Technology Profile: A Targeted Method for Treating Disease

    DNAbilize® Technology Profile: A Targeted Method for Treating Disease ➢ Antisense - molecules that interfere with the process of producing proteins inside cells (RNAi) ➢ Does not use a toxic agent to kill cells, but blocks production of proteins ➢ Advantage of specificity because it targets the dise

  7. Slide 7: Why Antisense DNA?

    Slide 7: Why Antisense DNA?

    Why Antisense DNA? • Antisense DNA inhibits the production of only the protein of interest. The specificity of the treatment means less side effects for the patient • Antisense DNA blocks the problem protein from being made. Other therapeutics attempt to inhibit a protein already in circulation. Wit

  8. Slide 8: DNAbilize Technology Summary

    Slide 8: DNAbilize Technology Summary

    DNAbilize® Technology Summary Core of the technology is a combination of a stable DNA backbone and a neutral lipid (fat cell) delivery that mimics the cell membrane SAFE: No toxicity from the DNA or the lipid delivery, no blood clotting or liver toxicity SYSTEMIC: Allows for whole body distribution

  9. Slide 9: Liposomal Drug Uptake by Cells

    Slide 9: Liposomal Drug Uptake by Cells

    Liposomal Drug Uptake by Cells Inhibitory DNA incorporated into liposomes that resemble the cell membrane seamlessly merge with the cell, releasing the DNA drug into the cytoplasm Outside the diseased cell: Inside the diseased cell: Liposome in the blood stream Significant uptake of the carrying DNA

  10. Slide 10: Clinical Pipeline

    Slide 10: Clinical Pipeline

    Clinical Pipeline Target Indications Preclinical IND Phase I Phase II Prexigebersen (BP1001) AML* Prexigebersen (BP1001) CML* Prexigebersen Solid (BP1001) tumors BP1002 (Liposomal Bcl2) Lymphoma DNAbilize™ Technology Ready to out-license *Prexigebersen (BP1001) has received orphan drug designation f

  11. Slide 11: Continuing Improvements in Product Manufacturing and Design

    Slide 11: Continuing Improvements in Product Manufacturing and Design

    Continuing Improvements in Product Manufacturing and Design ➢ Through our dose-escalating Phase 1 trial we upgraded our supplier base with the goal of increased capability and capacity ➢ Several test batches have confirmed the potency of our currently manufactured drug product in AML cells. ➢ Identi

  12. Slide 12: Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen

    Slide 12: Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen

    Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen ➢ Target of drug is a protein called Grb2, important in growth and proliferation of cancer cells ➢ Phase I trial for AML, CML, & MDS patients refractory or resistant to current therapies ➢ Patients averaged 6 prior therapies ➢ D

  13. Slide 13: Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results

    Slide 13: Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results

    Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results ➢ Low Dose Ara C (LDAC) is the current frontline treatment for elderly AML ➢ The safety trial for the combination of LDAC + prexigebersen was evaluated in relapsed AML patients, average age 75 years old ➢ 3 evaluable patients i

  14. Slide 14: Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy

    Slide 14: Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy

    Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy • Safety segment completed, demonstrated no negative synergies using prexigebersen together with frontline therapy, low dose chemotherapy (LDAC) – Treatment of newly diagnosed AML patients who are fragile – Efficacy tri

  15. Slide 15: Advances in the CML Program

    Slide 15: Advances in the CML Program

    Advances in the CML Program Presentation at the December 2016 American Society of Hematology Annual Meeting • BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia • Prexigebersen (BP1001) decreased the proliferation of Gleevec® (imatinib)-resistant CML cells in a dose-dependent manner • Prex

  16. Slide 16: Preclinical Pipeline

    Slide 16: Preclinical Pipeline

    Preclinical Pipeline Validating DNAbilize™ with Key Opinion Leaders: • Establishing prexigebersen in triple negative and inflammatory breast cancer and advanced ovarian cancer with the MD Anderson Cancer Center – Advances in liposome properties enhancing solid tumor outcomes • Developing clinical an

  17. Slide 17: Achievements and Upcoming Milestones

    Slide 17: Achievements and Upcoming Milestones

    Achievements and Upcoming Milestones  Enrolling and treating patients in Value propositions being advanced: prexigebersen Phase II efficacy trial for • Enrollment of first 19 patients in Phase II AML with an interim analysis to be completed with potential for switch to registration trial  Safety s

  18. Slide 18: Leadership

    Slide 18: Leadership

    Leadership Peter Nielsen Co-Founder, President, Chief Executive Officer and Chief Financial Officer • Officer and Director since founding Company in 2007 • Manufacturing development and evolution of engineered product design William Hahne, M.D. Vice President of Clinical Research • Medical consultan

  19. Slide 19: Scientific Advisory Board

    Slide 19: Scientific Advisory Board

    Scientific Advisory Board Jorge Cortes, M.D. Chairman • M.D. from la Facultad de Medicina, Universidad Nacional Autónoma de México • Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML and CML sections, and Deputy Chair of the Department of Leukemia at The University of T

  20. Slide 20: Competitors with DNA/RNA Therapeutics

    Slide 20: Competitors with DNA/RNA Therapeutics

    Competitors with DNA/RNA Therapeutics Company Bio-Path Ionis Alnylam Dicerna Drug DNA DNA siRNA siRNA Delivery Uncharged lipids None Sugar Sugar Blood clotting Safety Non-toxic Liver toxicity Liver toxicity toxicity Symbol BPTH IONS ALNY DRNA Share price $0.41 $52.93 $121.07 $6.27 Market cap $50 M $

Source: Internet Archive copy of biopathholdings.com

More decks from Bio-Path Holdings, Inc.

All 11 Bio-Path decks